Silencing of ADAMTS9-AS2 prohibited GBM proliferation, migration, and invasion and decreased the therapeutic effects of TMZ treatment by directly binding to the RRM and Znf_RanBP2 domains of FUS, leading to increased FUS protein expression (Yan et al., 2019). The gene discussed is FUS; the disease is glioblastoma.